CIBIS,MERIT-HF,and COPERNICUS Trial Outcomes: Do They Complete the Chapter on -Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Drugs?

Abstract

References

1. Rosen MR . Classification of antiarrhythmic drugs. Card Electrophysiol Rev 4:181-181, 2000

2. Johnson EA , McKinnon MG . The differential effects of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation. J Pharmacol Exp Ther 120:460-460, 1956

3. Jervell A , Lange-Nielsen F . Congenital deaf mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J 54:59-59, 1957

4. Selzer A , Wray HW . Quinidine-syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30:17-17, 1964

5. Dessertenne F . La tachycardie ventriculaire a deux foyes opose variables. Arch Mal Coeur 59:63-63, 1966

6. Singh BN. Pharmacological Actions of Certain Cardiac Drugs and Hormones: Focus on Antiarrhythmic Mechanisms. PhD Thesis, 1971; Hertford College & University of Oxford, England. Futura Publishing Co, Mt. Kisco, NY, pp 1-98, 1991

7. Singh BN , Vaughan Williams EM . A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474. Br J Pharmacol 39:675-675, 1970

8. Singh BN , Vaughan Williams EM . The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 39:657-657, 1970

9. Singh BN , Vaughan Williams EM . Local anesthetic and antiarrhythmic actions of aprenolol relative to its effect on intracellular potentials and other properties of isolated cardiac muscle. Br J Pharmacol 38:749-749, 1970

10.

10. Singh BN , Vaughan Williams EM . Effects on cardiac muscle of the beta-adrenoceptor blocking drugs INPEA and LB46 in relation to their local anesthetic actions on nerve. Br J Pharmacol 43:10-10, 1071

11.

11. Singh BN , Hauswirth O . Comparative mechanisms of actions of antiarrhythmic drugs. Am Heart J 87:367-367, 1974

12.

12. Yusuf S , Peto R , Lewis J , Sleight P . Beta-blockade during myocardial infarction: An overview of randomized trials. Prog Cardiovasc Dis 27:335-335, 1985

13.

13. Reiter MJ . Antiarrhythmic impact of antiischemic, antifailure and other cardiovascular strategies. Card Electrophysiol Rev 4:194-194, 2000

14.

14. Leenen FHH . Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol 15(suppl A):2A-12A, 1999

15.

15. Meredith IT , Broughton A , Jennings GL , Esler MD . Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325(9):618-624, 1991

16.

16. Multicentre international study: Supplementary report. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Br Med J 12(6084):419-419, 1997

17.

17. Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction N Engl J Med 304(14):801-801, 1981

18.

18. Beta-blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 47(12):1707-1707, 1982

19.

19. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 6(3): 199-199, 1985

20.

20. ISIS-1 Collaborative Group . Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Lancet 1(8591):922-922, 1988

21.

21. Kendall MJ , Lynch KP , Hjalmarson A , Kjekshus J . Beta-blockers and sudden cardiac death. Ann Intern Med 123(5):358-358, 1995

22.

22. Hjalmarson A . Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postin- farction period. Am J Cardiol 80(9B):35J-35J, 1997

23.

23. Gottlieb SS , McCarter RJ , Vogel RA . Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339(8):489-489, 1998

24.

24. Hallstrom AP , Cobb LA , Yu BH , et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 68(10):1025-1025, 1991

25.

25. Schwartz PJ , La Rovere MT , Vanoli E . Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 85(1 suppl): 177-177, 1992

26.

26. Tan HL , Hou CJ , Lauer MR , Sung RJ . Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 122(9):701-701, 1995

27.

27. Reiter MJ , Reiffel JA . Importance of beta-blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82(4A):91-91, 1998

28.

28. Steinbeck G , Andersen D , Bach P , et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy to patients with symptomatic sustained tachyarrhythmias. N Engl J Med 327:987-987, 1992

29.

29. Wiesfeld AC , Crijns HJ , Tuininga YS , Lie KI . Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Pacing Clin Electrophysiol 19(7): 1026-1026, 1996

30.

30. Kjekshus J . Comments-beta-blcokers: Heart rate reduction a mechanism of benefit. Eur Heart J 6:29-29, 1985

31.

31. Chadda K , Goldstein S , Byington R , Curb JD . Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73:5003-5003, 1986

32.

32. Waagestein F , Bristow MR , Swedberg K , et al. Beneficial effects of metoprolol in diopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342:1441-1441, 1993

33.

33. Packer M , Colucci WS , Sackner-Bernstein JD , et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The Precise Trial. Circulation 94:2793-2793, 1996

34.

34. Packer M , Bristow MR , Cohn JN . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1349, 1996

35.

35. CIBIS Investigators and Committees . A radomized trial of beta-blockade and heart failure.The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765-1765, 1994

36.

36. MERIT-HEFT Study Group . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001-2001, 1999

37.

37. CIBIS-II Investigators and Committees . The cardiac insufficiency treated with bisoprolol. CIBIS II. Lancet 353:9-9, 1999

38.

38. Australia-New Zealand Heart Failure Research Collaborative Group . Randomised, placebo-controlled trial of cardevilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349:375-375, 1997

39.

39. Packer M , Coats AJS , Fowler MB , Hugo AK , Krum H , Mohacsi P , Rouleau JL , Tendera M , Castaigne A , Roccker EB , Schultz MK , DeMets DL , for the Carvedilol Prospective Randomized Cumulative Survival Study Group . Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651-1651, 2001

40.

40. Singh BN . Antiarrhythmic drugs: Reorientation of recent developments in the control of disorders of cardiac rhythm. Am J Cardiol 81:3D-3D, 1998